AKAleksandr P. Kovalenko

Aleksandr P. Kovalenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aleksandr P. Kovalenko has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevention of pathological skin scars (experimental study)

    by N.P. Korableva, N.S. Romanenkov, D.I. Kremlev, A.V. Kosulin, A.A. Nekrasov, A.P. Kovalenko, M.S. Miroshnichenko, P.V. Arbekov

    Objective. To estimate the efficacy of botulinum toxin type A in prevention of hypertrophic and keloid skin scars. Material and methods. Experimental animals were 3 rabbits Soviet Chinchilla breed. Five ellipsoid wounds were inflicted and then sutured on the outer surface of each ear. The right ear was control, and the left ear was experimental. After 7 days, 2 units of botulinum toxin type A were injected into the scars on the experimental ear. At the control points (14, 28, 42 days), scars were assessed visually. Biopsy was performed with assessment of fibroblasts and myofibroblasts. Results. Visual assessment of scars in the control group revealed hypertrophic scars in 4 out of 15 cases. In the experimental group, no hypertrophic scars were detected. In 42 days after botulinum toxin type A injection, there were fewer fibroblasts in the experimental group (p=0.01). The number of myofibroblasts in scar tissue of experimental animals in 14, 28 and 42 days after botulinum toxin type A injection was 2 times lower than in the control group (p=0.000003). Conclusion. Botulinum toxin type A is effective for prevention of hypertrophic and keloid scars due to its effect on fibroblasts and myofibroblasts.

  • Treatment of phantom pain syndrome with botulinum neurotoxin

    by A.P. Kovalenko, V.K. Misikov, T.V. Bazueva, I.V. Shrek, D.YU. Butko, S.S. Khvostov

    Introduction. Phantom pain syndrome (PhPS) occurs in up to 60—70% of cases of limb amputation. PhPS is classified as a variant of chronic neuropathic pain (NP). Opioids, gabapentin and pregabalin are often prescribed, but in many cases they are ineffective. Cases of successful use of botulinum neurotoxin A (BoNT) are described, but no correct studies or statistical data have been provided yet. The aim of the study is to study the structure of PhPS and the effectiveness of its treatment of BoNT. Material and methods. 47 male patients aged 20—51 years with PhPS (2—5 months after amputation), pain according to Visual Analogue Scale (VAS) ≥5 points or ≥3 points with pain dyssomnia were examined. All patients received combined analgesic therapy, which did not change. Patients were randomized into 2 groups that received subcutaneously: the 1st group (n=24) incobotulotoxin (incoBoNT) (100—350 IU), the 2nd group (n=23) 2% lidocaine solution (160—200 mg). Injections were performed in 1.5—2 cm increments of 3—5 IU at each point. The number of injection points and the total dosage depended on the area of the stump. Control points of the study: 3, 7, 14, 21, 90, and 180 days. VAS, DN4, Pain Detect, LANSS, HADS, nerve ultrasound, pain diary were used. Pain extremes, average values were estimated, and the original daily pain index (DPI) was calculated. Results. PhPS debut after 5.41±0.08 days, VASmax pain per day 7.2±0.08 points, DPI 67.4±0.4 points, 17.76±0.15 hours of pain per day, pain dyssomnia 4.82±0.1 hours. HADS is within the normal range in 90% of cases. Neuroma was found in 38% of ultrasound patients. 89% of NP were associated with cases of neuroma. After the absence of lidocaine effect on days 3 and 7, the 2nd group was withdrawn from the study. Patients were included in the 1st group. The effect of using BoNT on 3—7 days was up to 50%, by the 21st a 90% reduction in all major pain-related indicators (p<0.0001). There was no effect in 6 patients, all of them had neuromas. The 1st of them was diagnosed with BoNT resistance. The 1st of them underwent intra- and preineural administration of 50 units of incoBoNT with 50% efficacy after 3—7 days under ultrasound. After 90—180 days, PhPS persisted in 3 patients and returned in 1 patient (out of 41 patients): VASmax and DPI were 30% of the original, 2—3 hours a day, none of the patients reported pain dissomnia. 15 patients were evaluated for the effect of PhPS on the use of the prosthesis. For 9 of them, the PhPS excluded the possibility of using it. 5—9 days after the introduction of BoNT, they all started using the prosthesis. Conclusions. The use of incoBoNT in the treatment of PhPS is highly effective and safe, even against the background of pharmacoresistant cases. The use of local anesthetics in PhPS is proven to be ineffective. Subcutaneous administration of BoNT is simple and sufficient in 89%, except for some cases with neuroma, when intra- and perineural administration can be used. We verified neuromas in 38% of PhPS cases. 89% of NB cases were associated with neuromas. The use of BoNT reduces the duration of prosthetics.


  • Open Access

    Methodology of botulinum therapy in the treatment of dystonic scoliosis in generalized dystonia (clinical case)

    by V. K. Misikov, A. P. Kovalenko, A. A. Kondur

    Dystonic scoliosis as one of the forms of generalized dystonia is a highly disabling form of dystonia, which can lead to damage to internal organs (lungs, heart) and the peripheral nervous system, including the spinal cord. Almost always, those muscles that are involved in the formation of a dystonic posture in generalized dystonia have not been studied in terms of the effectiveness of treatment with botulinum toxin type A and are not reflected in the instructions. As a result, there is no understanding of the general motor interaction with differentiation into targeted and non-targeted muscles, administration doses and control methods.The aim of the work was to evaluate the efficacy and tolerability of high doses of botulinum toxin type A in dystonic scoliosis, as well as to present the introduction of botulinum toxin type A using ultrasound and electromyographic control. We have described a clinical case of a 19-year-old patient suffering from generalized dystonia with S-shaped dystonic scoliosis of the III degree. Deep brain stimulation was recommended as a treatment for the patient. During the waiting period for the timing of the operation, we attempted symptomatic therapy using the drug incobotulotoxin A. Over the next year and a half, 700 units of botulinum toxin type A were administered under ultrasound and electromyographic control every 3–4 months. As a result, treatment of trunk dystonia in the patient during the observation period led to a clinically significant decrease in the degree of curvature (from 37° to 27°, from III to II degree of scoliosis) in the absence of undesirable effects of the drug, including generalized muscle weakness. According to the repeated conclusion of the council of neurosurgeons, surgical intervention is not indicated for the patient due to the positive effect of the introduction of botulinum toxin type A.

  • Open Access

    Treatment of spasticity in patients with the consequences of traumatic brain injury

    by A. P. Kovalenko, I. A. Vozniuk, K. M. Naumov, V. Yu. Lobzin, S. Yu. Kirtaev

    Up to 16–20% of patients with a history of traumatic brain injury (TBI), regardless of its severity, suffer from pronounced spasticity, cognitive, vestibular and motor disorders. At the same time, data on the effectiveness of botulinum neurotoxin (BoNT) in the treatment of post-traumatic spasticity is lacking.Objective: to assess the effectiveness of peripheral myorelaxants (botulinum neurotoxin type A) in the treatment of past-traumatic spasticity.Patients and methods. 21 male patients aged 25 to 48 years with post-traumatic spastic hemiparesis (at least 6 months after the injury) were examined. 450 to 850 U (mean – 650 U) of BoNT (incobotulinumtoxin) was injected into the spastic muscles of the upper and lower extremities. The follow-up assessment of spasticity and paresis was performed 24±3 days after BoNT injection. Patterns of spasticity were studied: shoulder adduction, elbow joint flexion, forearm pronation, hand and finger flexion, hip adduction, shin flexion, foot flexion, toe flexion. The following methods were used: original methods of manual testing (MMT) of spasticity, Tardieu scale (TS), modified Ashworth scale (MAS), Medical Research Council Scale (MRCS) to assess paresis.Results and discussion. 24±3 days after incobotulotoxin administration, we observed a significant 1.5–2-fold decrease in spasticity angle (xS) and a reduction in the angle of neuromuscular reactivity (xV3) by 15–30° in all the studied patterns. Changes of xV1 (muscle extensibility) and xA (muscle strength) were not significant. No adverse reactions were observed. The use of MMT and TS has shown its effectiveness and specificity in the evaluation of spasticity and effectiveness of BoNT, and in the dynamics of muscle condition.Conclusion. The study showed the feasibility of using MMT and TS in the evaluation and assessment of spasticity, as well as the effectiveness and safety of incobotulinumtoxin (Xeomin) in dosages from 450 to 850 U in the treatment of spasticity of the upper and lower extremities in patients with the consequences of TBI.


  • Open Access

    Novel approaches to the treatment of cervical dystonia. The concept of dual navigation control

    by A. P. Kovalenko, Z. A. Zalyalova, A. F. Ivolgin

    Сervical dystonia (CD) is the most common type of focal dystonia (up to 50% of all dystonia cases). Botulinum neurotoxin (BoNT) injections is the treatment choice for CD. However, the effectiveness and tolerability of botulinum therapy in CD depends on the correct choice of target muscles and the accuracy of the BoNT injection. The publication presents literature data and our own clinical experience regarding the use of navigation in BoNT injections in CD.According to the majority of authors, the use of navigation equipment, such as ultrasound (US) and electromyography (EMG), definitely increases the effectiveness of CD treatment and reduces the likelihood of adverse events. For the first time, an algorithm for the diagnosis and treatment of CD is proposed, based on the use of the method of «double- (EMG and US) guided navigation», a variant for determining the comparative activity of muscles by the intensity of the EMG signal and the design of an individual «passport» of the CD. The possibilities of analyzing the US of muscles, drawing up an accurate treatment regimen, targeted administration of BoNT, and using a non-injectable EMG electrode are shown. We present 4 clinical cases demonstrating the advantages of the double- (EMG+US) guided navigation method over the EMG-guided navigation for injection. The proposed algorithm for the diagnosis and treatment of CD makes it possible to increase the effectiveness of treatment, optimize the costs of BoNT and diagnostic equipment (injection EMG needle).


  • Open Access

    Exo-rehabilitation of patients with spastic hemiparesis: high technology

    by Aleksandr S. Rodionov, Aleksandr P. Kovalenko, Dmitriy I. Kremlуоv, Dmitriy V. Averkiуev

    AIM: Walking disorders are a frequent consequence of stroke. New technologies, such as the use of robotic exoskeletons, can help with recovery, but their effectiveness has not yet been sufficiently proven. MATERIALS AND METHODS: Forty-two patients with spasticity and walking disorders (stroke duration from 1.5 to 4 years) were included in the study. The Tardieu Scale, Modified Ashworth scale, Medical Research Council Scale, 10 Meter Walk Test, Rivermead Mobility Index, Berg Balance Test, Rankin scale, and a Visual Analog Scale (to assess patient satisfaction with treatment) were used in assessments. The patients were randomized into 2 groups (n = 22 20): the first group received exoskeleton walk training with the powered exoskeleton, ExoAtlet, and the second group received physical therapy sessions, each for 1 hour daily over 10 days. Clinical evaluations of patients were performed at 3 timepoints: baseline (Day 1), and 12. RESULTS: Comparison of both groups at the second timepoint showed significantly better results (p 0.05) in the first group vs the second group. Walking speed increased due to balance training, correction of postural disorders, spastic muscle stretching, and stretch reflex suppression. CONCLUSION: The wearable powered ExoAtlet exoskeleton is a promising technology for improving walking (2 tables, bibliography: 13 refs).